Everest’s In-licensed Kidney Drug Meets Endpoints in Phase III Trial
publication date: Mar 14, 2023
Shanghai Everest Medicines reported its in-licensed kidney drug, Nefecon, met its Phase III endpoints in patients with primary IgA nephropathy (IgAN). In 2019, Everest acquired China rights to Nefecon from Sweden’s Calliditas Therapeutics in an agreement worth up to $121 million. Calliditas conducted the global Phase III trial, which enrolled 364 patients randomized 1:1 for Nefecon and placebo. Everest said the trial showed Nefecon is a disease modifying first-in-disease treatment for IgAN patients. The trial included a China arm that is expected to release final data in Q3 of 2023. More details....
Stock Symbol: (HK:1952)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.